Tempus AI, Inc. TEM
We endeavor to unlock the true power of precision medicine by creating Intelligent Diagnostics through the practical application of artificial intelligence, or AI, in healthcare. Intelligent Diagnostics use AI, including generative and agentic AI, to make laboratory tests more accurate, tailored, and personal. We make tests intelligent by connecting laboratory results to a patient's own clinical data, thereby personalizing the results. Our novel insight was realizing that all laboratory test results, genomic or otherwise, could be contextualized for a specific patient based upon that patient's unique characteristics, and technology could therefore guide therapy selection and treatment decisions to allow each patient to progress on their own unique path. The drugs recommended, the clinical trials explored, the care pathways evaluated, and the adverse events considered—all have the potential to be refined and enhanced when test results are connected to a patient's personal profile, enabling the right patient to be routed to the right therapy at the right time.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.27B | $693.4M | $531.8M | $320.7M | — |
| R&D | $172.9M | $149.3M | $90.3M | $83.2M | — |
| SG&A | $731.7M | $755.4M | $296.8M | $233.4M | — |
| Total operating expenses | $1.52B | $1.38B | $727.9M | $586.1M | — |
| Operating income | -$252.9M | -$691.1M | -$196.1M | -$265.4M | — |
| Pre-tax income | -$291.1M | -$701.3M | -$213.5M | -$289.1M | — |
| Income tax | $51.7M | $266.0K | $288.0K | $66.0K | — |
| Net income | -$245.0M | -$705.8M | -$214.1M | -$289.8M | — |
| EPS, basic | -1.41 | -6.23 | -4.20 | -5.30 | — |
| EPS, diluted | -1.41 | -6.23 | -4.20 | -5.30 | — |
| Shares, diluted (wtd. avg.) | 174,264 | 119,849 | 63,306 | 63,306 | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $604.8M | $341.0M | $165.8M | $303.7M | $278.5M |
| Receivables | $311.2M | $154.8M | $94.5M | — | — |
| Inventory | $51.7M | $38.4M | $28.8M | — | — |
| Total current assets | $1.17B | $667.6M | $350.3M | — | — |
| Property, plant and equipment | $89.2M | $58.1M | $61.7M | — | — |
| Goodwill | $470.2M | $73.3M | $73.4M | $53.1M | — |
| Other intangibles | $355.3M | $11.7M | $21.9M | — | — |
| Total assets | $2.27B | $926.1M | $564.1M | — | — |
| Accounts payable | $82.0M | $53.8M | $54.4M | — | — |
| Total current liabilities | $372.4M | $291.1M | $232.6M | — | — |
| Total liabilities | $1.78B | $869.8M | $840.7M | — | — |
| Retained earnings | -$2.40B | -$2.15B | -$1.40B | — | — |
| Total equity | $491.3M | $56.3M | -$1.38B | -$1.13B | -$807.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$218.1M | -$189.0M | -$214.3M | -$168.2M | — |
| Depreciation and amortisation | $32.1M | $26.4M | $21.3M | $16.7M | — |
| Stock-based compensation | $124.7M | $534.1M | $0 | $0 | — |
| Capital expenditure | $21.0M | $22.1M | $34.6M | $18.4M | — |
| Investing cash flow | -$398.4M | -$130.4M | -$40.3M | -$57.9M | — |
| Financing cash flow | $884.1M | $494.3M | $117.5M | $251.4M | — |
| Dividends paid | $0 | $5.6M | $5.6M | $5.6M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-145528.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | $320.7M | $531.8M | $693.4M | $1.27B |
| Gross profit | — | — | — | — | — |
| Net income | — | -$289.8M | -$214.1M | -$705.8M | -$245.0M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed Item 1.01
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 7370
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| GOOGL | Alphabet Inc. | $3.89T | 29.6x | 15.1% |
| META | Meta Platforms, Inc. | $1.63T | 27.4x | 22.2% |
| APP | AppLovin Corp | $87.39B | 26.7x | 70.0% |
| ZM | Zoom Communications, Inc. | $28.05B | 15.5x | 4.4% |
| FLUT | Flutter Entertainment plc | $13.90B | — | 16.6% |
| PINS | PINTEREST, INC. | $12.56B | 36.6x | 15.8% |
| FDS | FACTSET RESEARCH SYSTEMS INC | $11.78B | 21.3x | 5.4% |
| DOCN | DigitalOcean Holdings, Inc. | $10.96B | 37.0x | 15.5% |